Harmony Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Harmony Biosciences's estimated annual revenue is currently $36.4M per year.
- Harmony Biosciences received $200.0M in venture funding in March 2019.
- Harmony Biosciences's estimated revenue per employee is $148,673
- Harmony Biosciences's total funding is $1.1B.
- Harmony Biosciences has 245 Employees.
- Harmony Biosciences grew their employee count by 17% last year.
Harmony Biosciences Competitors & Alternatives
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Harmony Biosciences?
Patients are at the beginning, middle, and heart of all we do. Harmony Biosciences, LLC, is a privately-owned biopharmaceutical company. The company was established in October 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. Harmony Biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.keywords:N/A
Number of Employees
Employee Growth %
Harmony Biosciences News
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Expected to Announce Earnings of $0.25 Per Share. Posted by admin on Apr 23rd, 2022.
Harmony Biosciences is a commercial stage pharmaceutical company headquartered in Plymouth Meeting, PA. The Company was established by Paragon...
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY Get Rating) Director Jack Nielsen sold 4,195 shares of the company's stock in a...
PLYMOUTH MEETING, Pa., Oct. 26, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it wil ...
PLYMOUTH MEETING, Pa., Oct. 21, 2021 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced that it wil ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Harmony Biosciences Funding
|2019-03-14||$200.0M||Undisclosed||CR Group LP||Article|